Clinical trials: Hematologic
PTCH1 or SMO Activated Solid and Hematologic Tumors
LDE225 for Patients With PTCH1 or SMO Mutated Tumors
The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study
- Trial name
- SIGNATURE (NCT02002689)
- Testing
- LDE225
- Where
- 10 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Primary Objective: To estimate the probability of molecular complete remission at one year for the described sequential treatment approach, with nonablative hematopoietic transplantation, post transplant imatinib mesylate and…
- Trial name
- NCT00499889
- Testing
- Imatinib Mesylate, Fludarabine (Fludara), Busulfan
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Sickle Cell Disease
A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease
The purpose of this study is to assess the maximum tolerated dose, safety and pharmacokinetics of an investigational drug, intravenous (IV) citrulline, in subjects in steady-state sickle cell disease.
- Trial name
- NCT02314689
- Testing
- Intravenous (IV) citrulline
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Suvankar Majumdar
Immunosuppresion, Thrombocytopenia
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow.
- Conditions
- Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
- Trial name
- NCT00260689
- Testing
- Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Chronic Lymphocytic Leukemia
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune function in previously untreated…
- Trial name
- NCT03514017
- Testing
- Pembrolizumab, Ibrutinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma, Large-Cell, Diffuse
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma
This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent…
- Trial name
- ORCHARRD (NCT01014208)
- Testing
- OFATUMUMAB + DHAP, RITUXIMAB + DHAP
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 447 people
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Latin American Real-world Study in Acute Leukemia
The objective of the study is to describe the current epidemiology, treatment patterns, outcomes and healthcare resource use of adult patients diagnosed with relapsed/refractory (R/R) B-cell ALL and de novo AML in 4 Latin…
- Trial name
- LOYAL (NCT05166135)
- Where
- 14 sites in Argentina, Brazil and 2 more
- Volunteers
- 589 people
- Sponsor
- Pfizer
Renal Insufficiency, Chronic, Iron-Deficiency Anemia
Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
- Trial name
- AEGIS-CKD (NCT02968368)
- Testing
- Ferric maltol
- Where
- 27 sites in United States
- Volunteers
- 167 people
- Sponsor
- Shield Therapeutics
Myelodysplastic Syndrome (MDS)
Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome
The purpose of the study is to determine whether azacitidine is safe and effective in the treatment of Chinese patients with higher risk Myelodysplastic Syndromes (MDS).
- Trial name
- NCT01599325
- Testing
- Azacitidine
- Where
- 11 sites in China
- Volunteers
- 72 people
- Sponsor
- Celgene
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Chronic Lymphocytic Leukemia
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 under two different dosing schedules with the objective of defining the dose limiting toxicity and maximum tolerated dose.
- Trial name
- NCT00481091
- Testing
- ABT-263
- Where
- 10 sites in United States, Australia and 2 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- FREEDOM (NCT03755518)
- Testing
- FEDRATINIB
- Where
- 35 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Celgene
Sickle Cell Disease
Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting
The Emergency Department has been the standard location where patients with Sickle Cell Disease (SCD) go to seek care for the treatment of acute painful events.
- Trial name
- ESCAPED (NCT02411396)
- Where
- 3 sites in United States
- Volunteers
- 483 people
- Sponsor
- Johns Hopkins University
Immune Mediated Anemia, Immune Mediated Thrombocytopenia
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be.
- Conditions
- Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
- Trial name
- NCT05502783
- Testing
- fostamatinib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lymphocytic Leukemia, CLL Progression
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK inhibitor (BTKi) or BCL-2 inhibitor.
- Conditions
- Chronic Lymphocytic Leukemia, CLL Progression, CLL/SLL
- Trial name
- NCT04149821
- Testing
- Umbralisib, Ublituximab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Iron Deficiency Anemia
To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia
The primary objective is to demonstrate the efficacy of ferric carboxymaltose (FCM) given in a simple dosing regimen in correcting iron deficiency anaemia (IDA), by demonstrating non-inferiority to treatment with the currently…
- Trial name
- NCT03591406
- Testing
- Ferric carboxymaltose, Iron sucrose
- Where
- China
- Volunteers
- 371 people
- Sponsor
- Vifor (International) Inc.
Iron Deficiency Anaemia, Inflammatory Bowel Disease
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).
- Conditions
- Iron Deficiency Anaemia, Inflammatory Bowel Disease, Crohn's Disease
- Trial name
- AEGIS-2 (NCT01352221)
- Testing
- ST10
- Volunteers
- 128 people
- Sponsor
- Shield Therapeutics
Thrombocytopenia Associated With Chronic Liver Disease
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia
This is a phase 2, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag for Japanese subjects with thrombocytopenia associated with chronic liver disease.
- Trial name
- NCT02227693
- Testing
- avatrombopag
- Where
- 14 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Eisai Co., Ltd.
Acute Chest Syndrome, Sickle Cell Disease
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
The purpose of this study is to determine the feasibility of performing a larger multicenter phase III trial to assess the effects of unfractionated heparin (UFH) in acute chest syndrome (ACS).
- Trial name
- NCT02098993
- Testing
- Unfractionated heparin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Craig Seaman
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.